1. Introduction {#sec1-ijms-21-03823}
===============

Inflammation, the body's immune response to stimulus, is a complex biological process/defense mechanism that is triggered by external or internal stimuli. It is associated with minor infections/injuries and with major disorders such as cancer, cystitis, arthritis, asthma, and psoriasis \[[@B1-ijms-21-03823]\]. In renal disease, mesangial cells (MCs) play a vital role in the evolution of immune-mediated inflammation. It has been shown that tumor necrosis factor-α (TNF-α) levels are associated with the development of nephropathy \[[@B2-ijms-21-03823]\]. Renal expression and circulating levels of bioactive TNF-α increase in lupus nephritis and correlate with disease activity \[[@B3-ijms-21-03823]\]. TNF-α has been implicated in renal inflammation by its upregulation of inflammatory genes such as cyclooxygenase-2 (COX-2), cytosolic phospholipase A~2~ (cPLA~2~), prostaglandin E~2~ (PGE~2~), matrix metalloproteinase-9 (MMP-9), and inducible nitric oxide synthase (iNOS) \[[@B4-ijms-21-03823],[@B5-ijms-21-03823]\]. Eicosanoids, which are involved in immune-mediated renal inflammatory diseases, are generated from arachidonic acid metabolism via cPLA~2~ and COX-2. We previously identified some traditional Chinese medicines that were effective in treating TNF-α-induced MC inflammation via downregulation of cPLA~2~ and COX-2 \[[@B6-ijms-21-03823]\]. Several other studies also indicated the significance of MMPs and tissue inhibitors of metalloproteinases (TIMPs) in the progression of glomerulonephritis \[[@B7-ijms-21-03823]\]. The production of nitric oxide (NO) is catalyzed by NO synthase (NOS), which degrades L-arginine to L-citrulline and NO. iNOS is one NOS isoform that is expressed by macrophages and other tissues in response to (pro) inflammatory mediators \[[@B8-ijms-21-03823]\]. Therefore, the modulation of MC responses could offer a pathophysiology-based therapeutic approach to prevent glomerular injury.

To alleviate chronic inflammation and its related pain, the current drugs of choice are nonsteroidal anti-inflammatory drugs (NSAIDs) \[[@B8-ijms-21-03823]\]. However, long-term use of classical NSAIDs has been associated with complications, including gastrointestinal ulcers, gastroduodenal erosions, renal dysfunction, and hepatotoxicity, mainly because of their variable selectivity towards COX enzymes \[[@B9-ijms-21-03823]\]. These drawbacks led to the search for new synthetic anti-inflammatory agents, which has identified several new carbocyclic and heterocyclic small molecules that are in clinical use. For example, celecoxib, ramifenazone, and famprofazone are well-known examples of pyrazole-based anti-inflammatory drugs. However, serious side-effects, including bone marrow depression, water and salt retention, and carcinogenesis prompted researchers to continue the search for new anti-inflammatory drugs.

Among heterocyclic cores, 1,2,3-triazole enjoys a reputable position in the area of drug discovery. Easy synthesis/functionalization, ability to interact with bioreceptors, rigid, and stable structure are some of the leading reasons behind the popularity of this core. \[[@B10-ijms-21-03823]\] Similarly, organometallic compounds such as ferrocene are known for their high metabolic stability, redox behavior, lipophilic and non-toxic features. Recently, Guo and co-workers demonstrated that ferrocene-based compounds could significantly reduce the LPS-induced NO secretion, IL-6, and TNF-α levels \[[@B11-ijms-21-03823]\] The structure activity relationship (SAR) studies indicated that the presence of planar spacers attached to the ferrocene fragment is beneficial for the inhibition of NO production in the in vitro model. It has been suggested that the new classes of anti-malarial, anti-tubercular, and anti-microbial agents could be achieved by merging these two cores, i.e., ferrocene-triazole hybrids \[[@B12-ijms-21-03823]\]. Previously, we reported that 1,4-disubstituted 1*H*-1,2,3-triazoles (**F**, **X1**--**X5**, [Scheme 1](#ijms-21-03823-sch001){ref-type="scheme"}) inhibit NO production in in vitro models of lipopolysaccharide (LPS)-induced inflammation \[[@B9-ijms-21-03823]\]. Prompted by these results, we decided to use rat mesangial cells (RMCs) as an in vitro cell culture model to examine the effects of ferrocene-1*H*-1,2,3-triazole hybrids on TNF-α-induced inflammation. First, the cell viability of these compounds on RMCs were evaluated. Next, we explored the effect of these compounds on TNF-α-induced inflammation in vitro. In addition, we report two new crystal structures.

2. Results and Discussion {#sec2-ijms-21-03823}
=========================

2.1. Synthesis and Characterization {#sec2dot1-ijms-21-03823}
-----------------------------------

We previously reported the detailed synthesis, structural and electrochemical characterization of **X1**--**X5** \[[@B9-ijms-21-03823]\]. Briefly, these compounds were obtained in good yields and purity by azide-alkyne chemistry using ethynyl ferrocene and substituted amines. We were able to grow two new crystals (**X1** and **X5**) and the results are discussed below.

### X-ray Crystal Structure {#sec2dot1dot1-ijms-21-03823}

Single crystals of **X1** and **X5** were collected from dichloromethane solution after slow evaporation. The experimental details and the crystal data for **X1** and **X5** are given in [Table 1](#ijms-21-03823-t001){ref-type="table"}, while their molecular structures are shown in [Figure 1](#ijms-21-03823-f001){ref-type="fig"}a,b. The structural parameters for both ferrocenyl substituents in compounds **X1** and **X5** were within the normal ranges, and the iron atom is sandwiched almost perfectly centrally between the two cyclopentadienyl rings in compound **X1** compared with **X5**. The distance of iron from the two cyclopentadienyl rings differs slightly in the two compounds. The iron was observed at 1.649 (5) and 1.652 (5) Å from the plane defined by the two cyclopentadienyl systems in **X1** but at 1.642 (5) and 1.652 (5) Å in compound **X5**. In both structures, the ferrocene has adopted an eclipsed conformation. The NO~2~ group attached to the benzene ring formed dihedral angles of 5.160 (7)° in compound **X1** and 61.41 (7)° in compound **X5**. The variation in the dihedral angle may be associated with *ortho*- and *para*-substitution of the NO~2~ group in compounds **X1** and **X5**, respectively. Single-crystal data indicate nitro N--O bond lengths of 1.216 (5) and 1.212 (5) Å in compound **X1** and 1.205 (5) and 1.216 (5) Å in compound **X5**, respectively. The crystal data indicate an N--O double bond and involvement of greater resonance in the *para*-containing nitro group in **X1** compared with the *ortho*-substitution in compound **X5**.

As is clear from the structure ([Figure 1](#ijms-21-03823-f001){ref-type="fig"}), the benzene ring (C13--C18) and cyclopentadienyl ring (C6--C10) form dihedral angles to the central triazole ring (N1--N3/C11--C12) at 17.09 (8)° and 12.58 (8)°, respectively, in compound **X1**. However, the benzene ring (C13--C18) and cyclopentadienyl ring (C6--C10) form dihedral angles to the central triazole ring (N1--N3/C11--C12) at 9.56 (7)° and 34.83 (7)°, respectively, in compound **X5**. This variation is due to the presence of substituted nitro groups at different positions in these compounds. The details of the intermolecular hydrogen bonds present in both compounds **X1** and **X5** are summarized in [Table 2](#ijms-21-03823-t002){ref-type="table"}. Compound **X1** forms a dimer because of C---H⋯O interactions ([Figure 2](#ijms-21-03823-f002){ref-type="fig"}a) and is stabilized by packing because of *π*⋯*π* interactions ([Figure 2](#ijms-21-03823-f002){ref-type="fig"}b). Compound **X5** forms a one-dimensional polymeric structure because of C---H⋯N interactions ([Figure 2](#ijms-21-03823-f002){ref-type="fig"}c) and is also stabilized by packing due to *π*⋯*π* interactions ([Figure 2](#ijms-21-03823-f002){ref-type="fig"}d). The presence of such noncovalent interactions is very important in biological applications to allow understanding of many biological processes \[[@B13-ijms-21-03823]\].

2.2. In Vitro Characterizations {#sec2dot2-ijms-21-03823}
-------------------------------

### 2.2.1. Antioxidant Effect on RMCs {#sec2dot2dot1-ijms-21-03823}

To identify a non-toxic dose, we first examined the cell viability on RMCs of various concentrations of ferrocene (**F**) and ferrocene-1*H*-1,2,3-triazole hybrids **X1**--**X5** using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. As shown in [Figure 3](#ijms-21-03823-f003){ref-type="fig"}a, the compounds were noncytotoxic at concentrations up to 50 μg/mL. It is worthwhile to mention here that the incorporation of triazole fragment to the ferrocene did not affect the cell viability profile of the ferrocene. Since all the hybrid compounds exhibited similar cell viability effects on RMCs, it can be concluded that merging these two pharmaceutically active cores is a safe strategy. Accordingly, a concentration of 12.5 µg/mL ferrocene-1*H*-1,2,3-triazole hybrids was used for all subsequent experiments.

Free radicals have the main role in inflammation and are divided into two categories, including reactive oxygen species (ROS) and reactive nitrogen species (RNS). ROS contains superoxide (O~2~^−^), hydroxy radical (^●^OH), peroxy radical (ROO^●^) and H~2~O~2~. Superoxide (O~2~^−^) is mainly produced in the mitochondrial electron transfer chain. When the cell performs respiration to generate ATP, about 1%--3% of the electrons leak out in a series of transmission processes and combine with oxygen to produce superoxide \[[@B14-ijms-21-03823]\]. In addition, cells will also produce superoxide through nicotine adenine dinucleotide phosphate (NAD (P) H) oxidase. Next, to quantitate the free radicals (ROS) in cells and in the mitochondria, we performed dihydroethidium (DHE) and MitoSOX staining (mitochondrial staining) followed by flow cytometric analysis and immunofluorescence, respectively. The results of this study indicated that, except hybrids **X1** and **X5** ([Figure 3](#ijms-21-03823-f003){ref-type="fig"}b), all other compounds showed antioxidant activities. Though there is no exact explanation behind the ineffectiveness of **X1** and **X5**, the antioxidant behavior of other hybrids (**X2**, **X3** & **X4**) and reference (**F**) compounds could be attributed to the following: Firstly, ferrocene-1*H*-1,2,3-triazole hybrid compounds are electroactive and can undergo facile redox changes. This means they have a propensity to scavenge free radicals (or at least alter their level). The electron-donating capability of the hybrid compounds is largely governed by the core attached to the ferrocene ring. For instance, electrochemical studies suggested that compound **X4** (E~ox~ (onset) = 0.32 V) has more tendency to get oxidized than **X3** (E~ox~ (onset) = 0.34 V) and **X1** (E~ox~ (onset) = 0.39 V) \[[@B9-ijms-21-03823]\]. Interestingly, the same trend has been reflected in the antioxidant assay (antioxidant effect = **X4** \> **X3** \> **X1**). Secondly, it has been demonstrated that 1,2,3-triazole can be readily oxidized at the N1 position of the triazole core \[[@B15-ijms-21-03823]\], thus provide an additional site for radical scavenging by such hybrid compounds. Of the antioxidant compounds, **X2**--**X4** exhibited a significant antioxidant effect on mitochondrial free radicals ([Figure 3](#ijms-21-03823-f003){ref-type="fig"}c). Absorption, distribution, metabolism excretion, and toxicity (ADMET) calculations (vide infra) supported this observation too, i.e., mitochondrial localization of the compounds. However, all the compounds cannot induce antioxidant enzymes, including HO-1 or SOD-2 ([Supplementary Figure S1](#app1-ijms-21-03823){ref-type="app"}). Therefore, we suggest that the antioxidant mechanisms of these compounds were not via antioxidant enzyme expression. In the future, we can further explore the antioxidant mechanisms of these compounds.

### 2.2.2. Effect on iNOS Expression and NO Production in RMCs {#sec2dot2dot2-ijms-21-03823}

RNS contains nitric oxide (NO^•^) and peroxynitroso (ONOO^−^) anions. Nitric oxide is a gas with unpaired electrons produced by NOSs in tissues, which is widely distributed in the body and has many physiological functions, defense, signal transduction, etc. The peroxynitroso anion is produced by the reaction of NO^•^ and superoxide. It is a kind of free radical with extremely active and super destructive power \[[@B16-ijms-21-03823]\]. It has been shown that the progression of renal disease is associated with an increase in NO production and iNOS activity \[[@B17-ijms-21-03823]\]. However, NO is a very polar molecule that is easily oxidized, whereas nitrite is a stable oxidative metabolite of NO. Therefore, NO production was represented by the accumulation of nitrite. In the present study, we measured nitrite levels and iNOS expression by Griess assay and real-time polymerase chain reaction (PCR), respectively. As shown in [Figure 4](#ijms-21-03823-f004){ref-type="fig"}a, a 24-h treatment with TNF-α (10 ng/mL) led to a 34.79-times higher expression of iNOS compared with control. Upon addition of ferrocene-1*H*-1,2,3-triazole hybrids (except **X5**) to the culture of RMCs, the iNOS level decreased remarkably compared with TNF-α-treated RMCs (*p* \< 0.01). In a parallel experiment ([Figure 4](#ijms-21-03823-f004){ref-type="fig"}b), the production of NO was significantly increased in TNF-α-stimulated cells. Pretreatment with **X1**--**X5** decreased this TNF-α-induced response. Inhibition of NO and iNOS indicated that ferrocene-1*H*-1,2,3-triazole hybrids could protect against inflammation in RMCs.

To investigate whether ferrocene-1*H*-1,2,3-triazole hybrids could suppress iNOS gene expression in RMCs, the cells were treated with these compounds at a non-toxic dose of 12.5 μg/mL for 24 h and analyzed by real-time PCR. As shown in [Figure 4](#ijms-21-03823-f004){ref-type="fig"}c, compounds **F** and **X1**--**X5** did not spontaneously induce iNOS gene expression in RMCs. Among them, **X2** and **X4** attenuated endogenous iNOS expression, but only **F**, **X1**, and **X3** significantly cause this inhibition ([Figure 4](#ijms-21-03823-f004){ref-type="fig"}c). Compared with other compounds, **X5** was the weakest in inhibiting endogenous iNOS and did not reach statistical significance. The expression of endogenous iNOS in **X5** alone treatment is close to that in the control group ([Figure 4](#ijms-21-03823-f004){ref-type="fig"}c). It may explain why it did not inhibit the expression of iNOS under the stimulation of TNF-α ([Figure 4](#ijms-21-03823-f004){ref-type="fig"}a). From the results obtained, it seems that the triazole core has an important role in the suppression of iNOS expression. In compounds **X2** and **X5**, azole fragment is blocked by the substituents present at the *ortho* position of the ring attached to azole (see [Figure 1](#ijms-21-03823-f001){ref-type="fig"}b). In **X1** and **X3**, the substituents are present on the *para* position and did not block azole fragments (see [Figure 1](#ijms-21-03823-f001){ref-type="fig"}a), thus causing inhibition. This steric effect fact is also supplemented by a comparative low inhibition profile of ferrocene alone, e.g., without steric effect. In addition, we speculate that the structure of these compounds contains the iron in ferrocene to interact with NO induced by TNF-α, leading to decrease nitrite formation ([Figure 4](#ijms-21-03823-f004){ref-type="fig"}b). This may explain why **X5** does not inhibit TNF-α-induced iNOS expression but inhibits nitrite production. The ability of **F**, **X1**, and **X3** to suppress the NO concentration could be also ascribed to a number of factors, but we envision that the molecular weight (MW), hydrogen bonding capability, solubility profile, topology and planarity of the compounds played a major role here. Overall, these results implied that compounds **F**, **X1**, and **X3** were better at preventing the elevation of NO concentrations.

### 2.2.3. Effect on the Expression of Inflammatory Proteins in RMCs {#sec2dot2dot3-ijms-21-03823}

TNF-α is a pro-inflammatory cytokine that plays a vital role in human and experimental glomerulonephritis and lupus nephritis \[[@B3-ijms-21-03823],[@B4-ijms-21-03823]\]. TNF-α has been reported to up-regulate inflammatory genes in various cells. Both of COX-2 and cPLA~2~ can be considered as indicators of inflammation and play a vital role in several renal inflammatory diseases. In our previous study, we have established the relationship between COX-2 and cPLA~2~ and suggested that TNF-α enhances PGE~2~ generation via cPLA~2~/COX-2 upregulation in RMCs \[[@B4-ijms-21-03823]\]. In addition, increasing studies have reported the significance of MMPs and TIMPs in the progression of glomerulonephritis. MMP-9 produced by neutrophils participates in the progression of renal fibrosis \[[@B18-ijms-21-03823]\]. Therefore, we investigate whether ferrocene-1*H*-1,2,3-triazole hybrids regulate the expression of inflammatory proteins in RMCs, the protein levels of COX-2, cPLA~2~, and MMP-9 were examined. As demonstrated in [Figure 5](#ijms-21-03823-f005){ref-type="fig"}a and [Figure 6](#ijms-21-03823-f006){ref-type="fig"}a, treatment with all ferrocene-1*H*-1,2,3-triazole hybrids significantly (*p* \< 0.05) decreased the expression of all these proteins in RMCs in response to TNF-α treatment. The levels of transcription of COX-2 ([Figure 5](#ijms-21-03823-f005){ref-type="fig"}b) and MMP-9 ([Figure 6](#ijms-21-03823-f006){ref-type="fig"}b) were also examined. Among ferrocene-1*H*-1,2,3-triazole hybrids, **X3** and **X4** caused more significant inhibition of TNF-α-induced COX-2 mRNA level than **F** ([Figure 5](#ijms-21-03823-f005){ref-type="fig"}b), while **X2**, **X4**, and **X5** significantly attenuated more TNF-α-induced MMP-9 mRNA level than **F** ([Figure 6](#ijms-21-03823-f006){ref-type="fig"}b). These results indicate that combining ferrocene and triazole motifs is an intriguing strategy to achieve an enhanced anti-inflammatory effect. In all the cases, we observed that the ferrocene-1*H*-1,2,3-triazole hybrids are more active than the ferrocene alone. However, the cells-treated with **X3** spontaneously increased COX-2 protein expression ([Figure 5](#ijms-21-03823-f005){ref-type="fig"}c) and the cells treated with **X5** spontaneously increased MMP-9 transcription ([Figure 6](#ijms-21-03823-f006){ref-type="fig"}c). In addition, RMCs treated with **X2** do not decrease COX-2 mRNA level in response to TNF-α ([Figure 5](#ijms-21-03823-f005){ref-type="fig"}b). Taken together, among all the ferrocene-1*H*-1,2,3-triazole hybrids, **X4** demonstrated the best anti-inflammatory effect on RMCs. From the results of [Figure 5](#ijms-21-03823-f005){ref-type="fig"}a,b, we can speculate that the main pharmacological mechanism of **F**, **X1**, and **X2** may be to inhibit TNF-α-induced COX-2 protein synthesis rather than mRNA transcription inhibition. In contrast, the **X3**--**X5** group may inhibit COX-2 mRNA transcription hence protein levels. We further analyze the effect of these compounds on the activity of COX-2 and cPLA~2~. As shown in [Figure 5](#ijms-21-03823-f005){ref-type="fig"}d, treatment with all ferrocene-1*H*-1,2,3-triazole hybrids significantly decreased the activity of cPLA~2~ as well as COX-2 in RMCs in response to TNF-α treatment. In this study, we also proved that cPLA~2~ affects COX-2 activity by AACOCF~3~ (a cPLA~2~ inhibitor) pretreatment, which is consistent with our previous publication \[[@B4-ijms-21-03823]\]. On the inhibitory mechanisms of ferrocene-1*H*-1,2,3-triazole hybrids in TNF-α-induced MMP-9 expression, **X2** and **X4** mainly inhibit transcription level, but the rest of the compounds may affect enzyme activity ([Figure 6](#ijms-21-03823-f006){ref-type="fig"}a,b). It is worth noting that the treatment of healthy cells with **X3** and **X5** under a safe dose will cause side effects, because these two compounds cause the expression of inflammatory proteins. It is not recommended to use it in healthy food or for preventing inflammation in the future.

2.3. In Silico Studies {#sec2dot3-ijms-21-03823}
----------------------

### 2.3.1. ADMET Predictions {#sec2dot3dot1-ijms-21-03823}

To obtain more information on the bioactivity and potential use of the reported molecules as drugs, we predicted their ADMET; the results of this analysis are presented in [Table 3](#ijms-21-03823-t003){ref-type="table"}. From the data, it is clear that the compounds possess acceptable physicochemical, pharmacokinetic, and toxicity profiles. For example, all compounds returned positive results for blood--brain barrier (BBB) transition, gastrointestinal (GI) absorption, and oral bioavailability criteria, indicating their ability to pass through the BBB and be absorbed into tissues. Compounds **X1**, **X2**, and **X5** exhibited similar GI absorption (*p* = 0.8939), while compound **X3** (*p* = 0.8706) and compound **X4** (*p* = 0.8252) had comparatively lower probability of absorption. The fact that all compounds showed category III acute oral toxicity indicates that they may be acceptable for oral delivery. Moreover, all compounds showed the probability of mitochondrial localization, which is well reflected in the results of the antioxidant assays ([Figure 3](#ijms-21-03823-f003){ref-type="fig"}c). It should be noted that all these values are calculated and therefore, in vivo studies are required to confirm these observations.

### 2.3.2. Docking Results {#sec2dot3dot2-ijms-21-03823}

Molecular docking studies have become a common technique to identify molecular targets for treating disease. Using this method, one can easily predict the biological potential of compound(s), and active/catalytic sites within an enzyme. Biological results indicated that ferrocene-1*H*-1,2,3-triazole hybrids **X1**--**X5** exhibit neuroprotective effects via the inhibition of NO production in microglial cells (BV-2). To rationalize this observation at the supramolecular level, we carried out docking studies of the compounds with the enzymes established for participation in inflammatory processes. It is reported that compounds bearing 1,2,3-triazole core exhibit an anti-inflammatory effect via the inactivation of microglia localized COX isoenzymes \[[@B19-ijms-21-03823]\]. Similarly, Chuang et al. \[[@B20-ijms-21-03823]\] have shown that cPLA~2~ plays a crucial role in ROS/NO signaling in LPS activated BV2 cells; thus, cPLA~2~ can be considered as an intriguing therapeutic target for inflammation control.

In the present study, we carried out shape-based docking studies of compounds into the active sites of cPLA~2~ (apo form, PDB code: 1CJY) \[[@B21-ijms-21-03823]\] and COX-2 (PDB code: 6COX) \[[@B22-ijms-21-03823]\] using Autodock vina tools \[[@B23-ijms-21-03823]\]. Since the crystal structure of cPLA~2~ had some missing regions, it was modelled using an online server, SWISS Model prior to the docking studies \[[@B24-ijms-21-03823]\]. The results of the docking studies indicated that all hybrid compounds preferred to enter the active site of the enzyme and interact with the nearby residues ([Figure 7](#ijms-21-03823-f007){ref-type="fig"}). For instance, it has been reported that, in order to impart COX-2 inhibitory activity, a ligand should interact with conserved (His90), nonconserved (Arg513) and nearby residues (Arg120, Tyr355 and Glu524, Trp387, Phe518, Ser530, Arg120, Tyr355, Glu524 and Val523) of COX-2 via polar and nonpolar interactions \[[@B13-ijms-21-03823]\]. Our docking result indicated that the ferrocene-1*H*-1,2,3-triazole hybrids prefer to enter the active site of the target and interact via multiple H-bonds ([Table 4](#ijms-21-03823-t004){ref-type="table"}).

Docking studies with cPLA~2~ (PDB code: 1CJY) indicated that, except **X2**, compounds **X1**--**X5** did not make any contact with the catalytic residue Ser228 or with the "oxyanion hole" (residues Gly197/Gly198) of the enzyme \[[@B25-ijms-21-03823]\]. However, they interacted with the nearby residues of the catalytic site of cPLA~2~ ([Figure 8](#ijms-21-03823-f008){ref-type="fig"} and compiled in [Table 4](#ijms-21-03823-t004){ref-type="table"}). The binding propensity of the ligand is significantly controlled by the functionalities present over the phenyl ring of triazole fragment. Unfortunately, we found that the docking energies do not match with the observed activity. However, in both cases, we observed that compound **X2** has the highest binding energies than the others, which is not very well reflected in in vitro studies. This can be ascribed to several factors, but we envisaged that high molecular weight (MW), hydrogen bonding propensity, solubility, and structural rigidity played important roles here.

For instance, compound **X2** has five HBA units (due to two nitro groups), which explains why it showed high affinity and binding energy with the enzymes in docking studies. At the same time, compound **X2**, due to its comparatively higher MW ([Table 3](#ijms-21-03823-t003){ref-type="table"}), lower solubility (log*P* = 5.54, [Table 3](#ijms-21-03823-t003){ref-type="table"}), and less structural rigidity (due to the presence of rotatable biphenyl units) leads to lower in vitro activity. Similarly, compounds **X3** and **X4**, bearing halogen atoms over the phenyl ring with moderate MW and lowest number of HBA units showed high activities.

3. Materials and Methods {#sec3-ijms-21-03823}
========================

3.1. Synthesis and Characterization {#sec3dot1-ijms-21-03823}
-----------------------------------

All chemicals, except where stated otherwise, were obtained from Merck (Darmstadt, Germany) and used as received. The detailed synthesis and characterization of compounds 1-(4-nitrophenyl)-4-ferrocenyl-1*H*-1,2,3-triazole (**X1**), 1-(4,4′-dinitro-2-biphenyl)-4-ferrocenyl-1*H*-1,2,3-triazole (**X2**), 1-(3-chloro-4-fluorophenyl)-4-ferrocenyl-1*H*-1,2,3-triazole (**X3**), 1-(4-bromophenyl)-4-ferrocenyl-1*H*-1,2,3-triazole (**X4**), and 1-(2-nitrophenyl)-4-ferrocenyl-1*H*-1,2,3-triazole (**X5**) can be found in our previous report \[[@B9-ijms-21-03823]\]. Single-crystal X-ray diffraction for compounds **X1** and **X5** was carried out on a Stoe IPDS 2 diffractometer equipped with a graphite crystal monochromator situated in the incident beam for data collection at room temperature \[[@B26-ijms-21-03823]\]. The determination of unit cell parameters and data collection were performed using Mo-Ka radiation (λ = 0.71073 Å). \[[@B27-ijms-21-03823]\] Unit cell dimensions were obtained with least-squares refinements, and all structures were solved by direct methods with SHELXT2015 \[[@B28-ijms-21-03823],[@B29-ijms-21-03823]\]. All H atoms were located from difference-Fourier maps, but in the final cycles of refinement they were included in the calculated positions and treated as riding atoms: C-H = 0.93--0.98 Å with Uiso (H) = 1.2 Ueq (C). Selected geometric parameters (Å, º) of the compounds are listed in [Supplementary Tables S1 and S2](#app1-ijms-21-03823){ref-type="app"}.

3.2. In Vitro Characterizations of Synthesized Compounds {#sec3dot2-ijms-21-03823}
--------------------------------------------------------

### 3.2.1. Cell Culture in the Presence of Ferrocene-1*H*-1,2,3-Triazole Hybrids {#sec3dot2dot1-ijms-21-03823}

RMCs (from the American Type Culture Collection (ATCC; Rockville, MD, USA)) were cultured in Dulbecco's minimal essential medium containing 10% heat-inactivated fetal bovine serum (FBS) at 37 °C in a 5% CO~2~ atmosphere. For the measurement of protein expression, enzymatic activity, and mRNA levels, 2 × 10^5^ cells/well were seeded into 12-well plates. In anti-inflammation experiments, cells were starved in 0% FBS and cultured with or without **X1**--**X5** for 2 h prior to TNF-α (R&D Systems, Minneapolis, MN, USA) treatment for 24 h.

### 3.2.2. Viability Assay {#sec3dot2dot2-ijms-21-03823}

Cells were seeded at a density of 3 × 10^5^ cells per well into 96-well plates and treated with different concentrations of **X1**--**X5** (from 1.5625 to 100 μg/mL in 1% DMSO) for 24 h, followed by the addition of 0.5 mg/mL MTT (Merck) for another 2 h. The MTT solution was then discarded and 100 μL of DMSO (Merck) was added to dissolve the formazan crystals. The level of colored formazan was analyzed on a microplate reader (SpectraMax 250, Molecular Devices, San Jose, CA, USA) at a wavelength of 540 nm. The values were determined by comparing the optical density of the **X1**--**X5**-treated group with that of the vehicle-treated group (1% DMSO).

### 3.2.3. Gelatin Zymography {#sec3dot2dot3-ijms-21-03823}

MMP-9 expression was analyzed as previously described \[[@B30-ijms-21-03823]\]. Briefly, after treatment, the culture medium was collected and centrifuged at 10,000× *g* for 5 min at 4 °C to remove cell debris. Next, the supernatants were mixed with 5× nonreducing sample buffer and electrophoresed on a 10% polyacrylamide gel containing 0.15% gelatin. After electrophoresis, the gel was washed twice in 2.5% Triton X-100 and then incubated in developing buffer at 37 °C overnight. After incubation, the gel was stained with staining buffer (30% methanol, 10% acetic acid, and 0.5% (wt/vol) Coomassie brilliant blue). Gelatinolytic activity was observed as white bands on a blue background.

### 3.2.4. Nitrite Production {#sec3dot2dot4-ijms-21-03823}

After cell treatment, the conditioned medium was collected and analyzed for nitrite production by Griess assay \[[@B31-ijms-21-03823]\]. Briefly, 50 μL of a solution containing 4% sulfanilic acid, 0.2% N-(1-naphthyl) ethylenediamine dihydrochloride, and 10% phosphoric acid was added to 50 μL of conditioned medium. Absorbance reading was taken at 550 nm after samples were incubated at 25 °C for 10 min in the dark. The standard curve of various NaNO~2~ concentrations was used to calculate the NO production in the sample.

### 3.2.5. Western Blotting for Inflammatory Proteins {#sec3dot2dot5-ijms-21-03823}

Western blotting was conducted as previously described \[[@B4-ijms-21-03823]\]. Briefly, after the cell culture, RMCs were washed, scraped, collected, and centrifuged at 45,000× *g* for 1 h at 4 °C to yield the whole-cell extract. The whole-cell extracts were quantitated, adjusted for concentration, denatured, resolved with 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis, and transferred to polyvinylidene fluoride membranes (Millipore, Bedford, MA, USA). Membranes were incubated with primary anti-COX-2 (Cell Signaling Technology, Danvers, MA, USA), anti-cPLA~2~ (Cell Signaling Technology) or anti-GAPDH antibody, which was used as a loading control (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4 °C overnight and secondary anti-rabbit or anti-mouse horseradish peroxidase antibody for 1 h at room temperature. The immunoreactive signals detected by enhanced chemiluminescence reagents were developed using a LumiFlash Ultima chemiluminescent substrate horseradish peroxidase system (Visual Protein Biotech Corporation, Taipei, Taiwan). The densitometry units of COX-2, cPLA~2~ and GAPDH were quantified by ImageLab TM 5.0 Software (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

### 3.2.6. Real-time PCR {#sec3dot2dot6-ijms-21-03823}

Real-time PCR was performed using the CFX Connect Real-time PCR Detection System (Bio-Rad Laboratories) to determine the expression of inflammatory genes, as per the workflow steps described previously \[[@B4-ijms-21-03823]\]. Briefly, total RNA was extracted and provided as a template for cDNA reverse transcription. The thermal conditions used were 3 min at 95 °C, 40 cycles of 10 s at 95 °C and 30 s at 58 °C. Relative gene expression was determined by the 2^−ΔΔCt^ method. Gene expression was normalized relative to unstimulated cells and fold variation was normalized to levels of β-actin expression (an endogenous control). The primers used for real-time PCR were as follows: 5′--CGTGAAAAGATGACCCAGATCA--3′ (forward) and 5′--CTCCGG AGTCCATCACAATG--3′ (reverse) for β-actin; 5′--ACATTCAGGCAGCAGAGGA--3′ (forward) and 5′--CCACCACAGGCACAT CAC--3′ (reverse) for cPLA~2~, and 5′--CAAGAATCAAATTACC GCTGAAG--3′ (forward) and 5′--CGAAGGAAGGGAATGTTGTT--3′ (reverse) for COX-2; 5′--CGCTTTCACCAAGACTGTGA--3′ (forward) and 5′--GCATCCCAAGTACGAGTGGT--3′ (reverse) for iNOS.

### 3.2.7. cPLA~2~ and COX-2 Enzyme Activity {#sec3dot2dot7-ijms-21-03823}

The experimental procedure of COX-2 activity detection is in accordance with the manufacturer's instructions (Abcam, Cambridge, UK). The following are simple instructions: First, we established a standard curve by a series of diluted resorufin standards. Resorufin is a redox fluorescent probe that can be used to visualize cell respiration directly. Next, for sample preparation, 5 × 10^6^ cells treated without or with compounds in the presence of TNF-α were scraped off from the culture plate and washed with cold PBS. After centrifuging at 500× g for 3 min, we discarded the supernatant and resuspended the cell pellet in 0.2 mL of lysis buffer with protease inhibitor cocktail on ice for 5 min. After centrifuging at 12,000× g 4 °C for 3 min, we collected the supernatant used as the sample. Sample and COX-2 positive control were separately loaded into each of the 96 wells at 20 μL and then 2 μL DMSO (for total COX activity detection) and 2 μL COX-2 inhibitor (Celecoxib, for COX-2 activity detection) were added in two groups. Reaction mix reagents (containing COX Probe, Diluted COX Cofactor and COX Assay Buffer) at 68 μL were loaded into each well and mixed enough, using a multichannel pipette to add 10 µL diluted arachidonic acid/NaOH solution into each well to initiate the reaction at the same time. After addition of the arachidonic acid, the fluorescence (Ex/Em = 535/587 nm) was measured immediately in a kinetic mode once every 15 sec for at least 30 min. One Unit COX activity = amount of COX which generates 1.0 µmol of resorufin per min.

The activity of COX-2 in the test samples is calculated as:$$COX\ Activity = \left( \frac{B}{\mathsf{\Delta}{T\ } \times {\ M}} \right) = {pmol}/\min/{mg}\ {or}\ \mathsf{µ}U/{mg}$$ where

B = Amount of resorufin from Standard Curve (pmol).

ΔT = Reaction time (min).

M = Protein amount added into the reaction well (mg)

at pH 8.0, 25 °C.

Use the ΔRFU~535/587nm~ to obtain B pmol of resorufin generated by COX-2 during the reaction time (ΔT = T~2~ -- T~1~). where

RFU~S2~ is the sample (DMSO) reading at time T2.

RFU~S1~ is the sample (DMSO) reading at time T1.

RFU~I2~ is the inhibitor sample (Celecoxib) at time T2.

RFU~I1~ is the inhibitor sample (Celecoxib) at time T1.

PLA~2~ sample that can utilize arachidonoyl thio-PC as a substrate can be measured by colorimetric cPLA~2~ assay kit (Abcam). Among them, any residual sPLA2 can be removed from the samples by using a membrane filter with a molecular weight cut-off of 30,000. To avoid any measurement of iPLA2 activity in the sample, use the iPLA2-specific inhibitor Bromoenol Lactone. Briefly, we added 15 µL of assay buffer (non-enzymatic control), positive control (bee venom PLA2) and sample (including iPLA2-specific inhibitor) to wells. We initiated the reactions for 1 h at room temperature by adding 200 µL substrate solution. The addition of 10 µL of DTNB/EGTA to each well stopped enzyme catalysis and developed the reaction for 5 min at room temperature. The absorbance was read at 414 nm using a microplate reader (SpectraMax 250). The activity of cPLA~2~ in the test samples is calculated as:$${cPLA}_{2}Activity = \frac{\mathsf{\Delta}A414/\min}{10.66\ {mM} - 1}\  \times \ \frac{0.225\ {mL}}{0.01\ {mL}}\  \times \ Sample\ dilution = \mathsf{µ}{mol}/\min/mL$$ where

A414/min = $A414\ \left( {sample} \right) - A414\ \left( {blank} \right)/60\ \min$

ΔA414/min = (A414/min~Sample~ − A414/min~Inhibitor~)

3.3. In Silico Studies {#sec3dot3-ijms-21-03823}
----------------------

The physicochemical properties and oral bioavailability of compounds **X1**--**X5** were predicted using admetSAR 2 webserver. \[[@B32-ijms-21-03823],[@B33-ijms-21-03823]\]. SMILE formats (as input) of the molecules were generated using Marvin 16.11.28.0, 2016, ChemAxon (<http://www.chemaxon.com>). Shape-based molecular docking studies were performed on an Intel (R) Core (TM) i5 CPU (2.3 GHz) with a Windows 2010-based operating system. Cif files of the ligands were converted to PDB files which were further used for docking analysis. The ligands were docked into the active sites of human cPLA~2~ (PDB code 1CJY) and COX-2 (PDB code: 6COX). The crystal structures were downloaded from the Brookhaven Protein Data Bank (<http://www.rcsb.org>). The pdbqt format of the compound and enzyme were obtained using AutoDock Tools (ADT) 1.5.4 \[[@B34-ijms-21-03823]\]. Preparation of parameter files for grid and docking was done using the following parameters: grid box size of 108 × 86 × 78 Å with 0.375 Å spacing that included the whole enzyme. Autodock vina was used for the docking studies \[[@B35-ijms-21-03823]\]. The docking results were analyzed using PyMol \[[@B36-ijms-21-03823]\] for possible polar and hydrophobic interactions. Of the different conformations obtained, the least energetic and most stable conformation was selected.

4. Conclusions {#sec4-ijms-21-03823}
==============

A series of ferrocene-1*H*-1,2,3-triazole hybrids were investigated for their viability, anti-inflammatory, and antioxidant effects. X-ray single-crystal structure studies indicated that the position of the nitro group (*ortho* or *para*) controlled the structure of the compound (dimeric or polymeric) in the solid state. We found that, among all the ferrocene-1*H*-1,2,3-triazole hybrids, **X2**--**X4** exhibited antioxidant effect on mitochondrial free radicals, and among all, **X4** demonstrated the best anti-inflammatory effect on RMCs. In silico studies confirmed the safety of the compounds and their ability to bind to the active site of the pro-inflammatory factors. Overall, the results of the present study indicated that ferrocene-1*H*-1,2,3-triazole hybrid, **X4**, can be used as a lead to optimize and develop a new anti-inflammatory and antioxidant agent.
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![Structures of 1,4-disubstituted 1*H*-1,2,3-triazoles.](ijms-21-03823-sch001){#ijms-21-03823-sch001}

![The molecular structure of compounds (**a**) **X1** and (**b**) **X5** with atom labeling. Displacement ellipsoids are drawn at the 40% probability level.](ijms-21-03823-g001){#ijms-21-03823-f001}

![A view of the formation of dimer due to C---H⋯O interactions (**a**) and a packing diagram along the *b*-axis with *π*⋯*π* interactions (**b**), shown as pink dashed lines in **X1**. A view of the formation of a polymeric structure of **X5** due to C---H⋯N interactions (**c**) and packing diagram along the *a*-axis (**d**) are shown as pink dashed lines.](ijms-21-03823-g002){#ijms-21-03823-f002}

![The antioxidant effect of ferrocene-1*H*-1,2,3-triazole hybrids in RMCs. Effect of ferrocene-1*H*-1,2,3-triazole hybrids on cell viability. (**a**) RMCs were treated with twofold serial dilutions of ferrocene-1*H*-1,2,3-triazole hybrids for 24 h, and cell viability was determined by the MTT assay. Data are expressed as % of control (1% dimethyl sulfoxide (DMSO)-treated group) and each column represented the mean ± standard error of the mean (SEM) of four independent tests. (**b**,**c**) Intercellular ROS in RMCs treated with **F**, **X1**, **X2**, **X3**, **X4**, or **X5** at 12.5 μg/mL for 2 h at 6 h post-TNF-α (10 ng/mL) incubation were assessed using DHE fluorescence followed by flow cytometric analysis (**b**), and MitoSOX staining (mitochondrial staining) followed by immunofluorescence. Results are expressed as mean ± SEM of at least three repeated and independent assays, \* *p* \< 0.05; \*\* *p* \< 0.01 versus control; ^\#^ *p* \< 0.01; ^\#\#^ *p* \< 0.01 versus TNF-α treatment alone.](ijms-21-03823-g003){#ijms-21-03823-f003}

![Effect of ferrocene-1*H*-1,2,3-triazole hybrids on iNOS expression and NO production in RMCs. Cells were pretreated with the compounds at 12.5 μg/mL for 2 h and subsequently stimulated with TNF-α (10 ng/mL) for 24h. The expression of iNOS and NO in RMCs were determined by (**a**) real-time PCR analysis and (**b**) nitric oxide assay, respectively. (**c**) Cells were incubated without or with **F**, **X1**, **X2**, **X3**, **X4**, or **X5** at 12.5 μg/mL for 24 h. The mRNA was extracted, reverse transcribed, and then analyzed the iNOS expression by real-time PCR. Data are expressed as fold of control (1% DMSO-treated group) and each column represents the mean ± SEM of at least three repeated and independent assays. Asterisks indicate a significant difference compared with the control group, \*\* *p* \< 0.01. Hashes indicate a significant difference compared with the TNF-α-treated group, ^\#\#^ *p* \< 0.01.](ijms-21-03823-g004){#ijms-21-03823-f004}

![Effect of ferrocene-1*H*-1,2,3-triazole hybrids on the protein expression of cPLA~2~ and COX-2 in RMCs. (**a**,**c**) Western blot assay to detect COX-2 and cPLA~2~ expression in cell lysate. (**b**) The COX-2 mRNA level was determined by real-time PCR. The sequence of addition of TNF-α reagent and compounds was as follows. In panels (**a**,**b**), RMCs were treated with ferrocene-1*H*-1,2,3-triazole hybrids (12.5 μg/mL) for 2 h and then exposed to TNF-α for another 24 h. In panel (**c**), RMCs were treated without or with **F**, **X1**, **X2**, **X3**, **X4**, or **X5** at 12.5 μg/mL for 24 h. COX-2 and cPLA~2~ expression were measured by comparison with that of GAPDH (internal control). In panel (**d**), the enzyme activity assay kits to detect of endogenous cPLA~2~ and COX-2 activity in RMC cell lysate (6 μg) stimulated without or with ferrocene-1*H*-1,2,3-triazole hybrids or AACOCF3 (AA) in the presence of 10 ng/mL TNF-α. Data were obtained from at least three independent experiments and are expressed as mean ± SEM. One-way analysis of variance (ANOVA) followed by Bonferroni's multiple-comparisons test was used to identify significant differences between multiple groups. Asterisks indicate a significant difference compared with the control group, \*\* *p* \< 0.01. Hashes indicate a significant difference compared with the TNF-α-treated group, ^\#\#^ *p* \< 0.01; ^\#^ *p* \< 0.05.](ijms-21-03823-g005){#ijms-21-03823-f005}

![Effect of ferrocene-1*H*-1,2,3-triazole hybrids on MMP-9 expression in RMCs. RMCs were treated with ferrocene-1*H*-1,2,3-triazole hybrids (12.5 μg/mL) for 2 h and then exposed to TNF-α for an additional 24 h. (**a**) MMP-9 expression was examined by gelatin zymography of the culture media. GAPDH was used as an internal control and examined by Western blotting. Densitometric quantification of MMP-9 in culture media is presented. (**b**) The mRNA levels of MMP-9 and β-actin were determined by real-time PCR. Results are presented as the mean ± SEM. Data are combined from three independent experiments with three replicate samples per group in each experiment. One-way ANOVA and Bonferroni's multiple-comparisons tests were used to identify significant differences between multiple groups. Asterisks indicate a significant difference compared with the control group, \*\* *p* \< 0.01. Hashes indicate a significant difference compared with the TNF-α-treated group, ^\#\#^ *p* \< 0.01. (**c**) Cells were treated without or with **F**, **X1**, **X2**, **X3**, **X4**, or **X5** at 12.5 μg/mL for 24 h. MMP-9 mRNA level was determined by real-time PCR.](ijms-21-03823-g006){#ijms-21-03823-f006}

![Molecular docking of hybrid compounds **X1** (**a**), **X2** (**b**), **X3** (**c**), **X4** (**d**), and **X5** (**e**) with cyclooxygenase-2 (PDB code: 6COX).](ijms-21-03823-g007){#ijms-21-03823-f007}

![Molecular docking of hybrid compounds **X1** (**a**), **X2** (**b**), **X3** (**c**), **X4** (**d**), and **X5** (**e**) with cPLA~2~ (PDB code: 1CJY).](ijms-21-03823-g008){#ijms-21-03823-f008}

ijms-21-03823-t001_Table 1

###### 

Experimental details and crystal structure data for compounds **X1** and **X5**.

  Experimental Details                                                           Crystal Data of X1                          Crystal Data of X5
  ------------------------------------------------------------------------------ ------------------------------------------- -------------------------------------------
  CCDC                                                                           1537323                                     1537684
  Chemical formula                                                               C~18~H~14~FeN~4~O~2~                        C~18~H~14~FeN~4~O~2~
  *M*r                                                                           374.18                                      374.18
  Crystal system, space group                                                    Monoclinic, P21/c                           Monoclinic, P21/c
  Temperature (K)                                                                296                                         293
  *a*, *b*, *c* (Å)                                                              11.1502 (7), 5.7600 (2), 24.1625 (12)       10.1528 (7), 13.9830 (6), 11.2383 (7)
  *α*, *β*, *γ* (°)                                                              90.000 (4), 95.892 (4), 90.000 (4)          90.000 (4), 100.475 (5), 90.000 (4)
  *V (Å^3^)*                                                                     1543.64 (14)                                1568.87 (16)
  *Z*                                                                            4                                           4
  *Radiation type*                                                               Mo *Kα*                                     Mo *Kα*
  μ (mm^−1^)                                                                     1.00                                        0.98
  Crystal size (mm)                                                              0.50 × 0.25 × 0.11                          0.72 × 0.37 × 0.13
  Data collection Diffractometer                                                 STOE *IPDS* 2                               STOE *IPDS* 2
  Absorption correction                                                          Integration (*X-RED32*; Stoe & Cie, 2002)   Integration (*X-RED32*; Stoe & Cie, 2002)
  *T*~min~, *T*~max~                                                             0.755, 0.945                                0.675, 0.900
  No. of measured, independent and observed \[*I* \> 2 *σ* (*I*)\] reflections   8127, 2976, 2356                            7441, 3027, 2510
  *R* ~int~                                                                      0.028                                       0.027
  (sin *θ*/*λ*) max (Å^−1^)                                                      0.614                                       0.615
  Refinement *R* \[*F*^2^ \> 2 *σ* (*F*^2^)\], *wR* (*F*^2^), *S*                0.035, 0.094, 1.01                          0.028, 0.073, 1.04
  No. of reflections                                                             2976                                        3027
  No. of parameters                                                              226                                         226
  No. of restraints                                                              12                                          0
  H-atom treatment                                                               H-atom parameters constrained               H-atom parameters constrained
  Δ*ρ*~max~, Δ*ρ*~min~ (e Å^−3^)                                                 0.58, −0.36                                 0.21, −0.22

ijms-21-03823-t002_Table 2

###### 

Hydrogen-bond geometry (Å, °) of compounds **X1** and **X5**.

  D---H⋯A           D---H   H⋯A    D⋯A         D---H⋯A
  ----------------- ------- ------ ----------- ---------
  Compound **X1**                              
  C17---H17⋯O1^i^   0.93    2.53   3.388 (3)   154.4
  Compound **X5**                              
  C14---H14⋯N2^i^   0.93    2.57   3.428 (2)   154.4

ijms-21-03823-t003_Table 3

###### 

Pharmaceutical prediction of in silico ADMET properties.

  Code   Physicochemical Properties   Pharmacokinetics   Toxicity Parameters                                                       
  ------ ---------------------------- ------------------ --------------------- ------- -------- -------- ------- ----------------- ------------
         MW^a^                        HBA^b^             HBD^c^                RB^d^   log*P*   GIA^e^   OB^f^   Carcino genesis   Irritation
  X1     374.18                       5                  0                     3       3.96     \+       \+      −                 \+
  X2     495.28                       7                  0                     5       5.54     \+       \+      −                 −
  X3     381.62                       3                  0                     2       4.85     \+       \+      −                 −
  X4     408.08                       3                  0                     2       4.82     \+       \+      −                 \+
  X5     374.18                       5                  0                     3       3.96     \+       \+      −                 \+

a = Molecular weight, b = Hydrogen bond acceptor, c = Rotatable bonds, d = Hydrogen bond donor, e = Gastrointestinal absorption, f = Oral bioavailability.

ijms-21-03823-t004_Table 4

###### 

Binding energy and interacting residues of **X1**--**X5** for COX-2 and cPLA~2~.

  PDB    Compound Code   H-bonding Site Residues                  Binding Energy (kcal/mol)   Distance (A)
  ------ --------------- ---------------------------------------- --------------------------- -------------------------
  6COX   X1              Arg120, Tyr355                           −9.04                       2.9, 3.1
  6COX   X2              Gln203, Tyr409                           −10.33                      2.7, 3.0, 3.2
  6COX   X3              Tyr115                                   −7.75                       2.9
  6COX   X4              Tyr115                                   −8.23                       2.9, 3.0
  6COX   X5              Arg513, Tyr355, Ser353, His90            −9.35                       2.7, 2.8, 3.1, 3.4
  1CJY   X1              Gly551, Leu552, Lys595                   −6.97                       3.5, 3.2, 2.6
  1CJY   X2              Gly197, Gly198, Ser228, Asp549, Gly551   −11.51                      2.5, 2.6, 2.8, 3.0
  1CJY   X3              Asp345                                   −9.13                       2.8
  1CJY   X4              Asp345, Trp346, Pro559                   −9.94                       2.9, 3.2, 3.4
  1CJY   X5              Asn262, Val407, Asn682, Gly684           −7.15                       2.7, 2.8, 3.0, 3.1, 3.5
